AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 798469
Drug: Clopimozide (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopimozide (weekly administration)
Trial: 29260533
Drug: C+E group
RxNorm normalized name: meningococcal group C polysaccharide
DrugBank: Meningococcal polysaccharide vaccine group C (DB13890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C+E group (convention + esomeprazole 40 mg/d intravenously for 1 week)
Trial: 29260533
Drug: C group
RxNorm normalized name: chimeric antigen receptor (CAR)-T cell therapy targeting G protein-coupled receptor class-C group-5 member-D (GPRC5D)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C group (convention treatment only)
Trial: 19614946
Drug: glulisine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glulisine monotherapy
Trial: 15481762
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO) 6 g/d
Trial: 8513524
Drug: Erythromycin 500
RxNorm normalized name: erythromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 500 mg diluted in 250 ml dextrose 5% administered 30 min before induction of anaesthesia (Group E)
Trial: 8513524
Drug: Dextrose 5%
RxNorm normalized name: Dextrose 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose 5% infusion (Group P)
Trial: 28811749
Drug: Cocoa Flavanols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa Flavanols (900 mg CF)
Trial: 28811749
Drug: Placebo (13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (13 mg CF)
Trial: 18458645
Drug: Bilateral oophorectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral oophorectomy with no previous hormone therapy use
Trial: 18458645
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (HT) use within 5 years of bilateral oophorectomy
Trial: 18458645
Drug: No hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No hormone therapy use
Trial: 15315266
Drug: SKI306X 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKI306X 200 mg three times daily
Trial: 15315266
Drug: Diclofenac 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 100 mg sustained release once daily
Trial: 11751710
Drug: Dexamethasone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (1 mg) - acute administration
Trial: 11751710
Drug: Dexamethasone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (1 mg) - prolonged administration
Trial: 11751710
Drug: Placebo -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - prolonged administration
Trial: 11751710
Drug: Dexamethasone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (1 mg) - prolonged administration in lean subjects
Trial: 3738655
Drug: Vincristine sulphate
RxNorm normalized name: Vincristine sulphate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vincristine sulphate bolus of 1.5 mg/m2
Trial: 21871635
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate dispersible tablets (5 mg Zn)
Trial: 21871635
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate solution (5 mg Zn/5 mL)
Trial: 20976374
Drug: Aspirin -
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin - 200 mg/day (Group Aspirin - GA)
Trial: 20976374
Drug: Warfarin at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin at individually-adjusted doses (Group Warfarin - GW)
Trial: 18545068
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg coadministered with simvastatin 20 mg
Trial: 15695129
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg (monotherapy)
Trial: 18545068
Drug: Simvastatin monotherapy
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin monotherapy group
Trial: 7930468
Drug: Tamoxifen (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (10 mg bid)
Trial: 3339948
Drug: Veralipride (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veralipride (200 mg/day for 20 days) + Naloxone (1.6 mg/h for 4 h)
Trial: 31205195
Drug: Asenapine (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asenapine (10-20 mg/d)
Trial: 16585867
Drug: Preoperative accelerated
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative accelerated hyperfractionated radiotherapy with concurrent cisplatin followed immediately by surgery and intraoperative radiotherapy, completed with early postoperative weekly paclitaxel, two additional cisplatin cycles, and concurrent once‐daily radiotherapy beginning on day 28 after surgery
Trial: 31494289
Drug: Implementation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implementation of a brachial plexus biological dose constraint in IMPT plans (cohort B).
Trial: 31494289
Drug: IMPT plans
RxNorm normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IMPT plans without BP biological dose constraint (cohort A).
Trial: 29258851
Drug: Synthetic granular
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic granular calcium phosphate compound (CPC)
Trial: 16622086
Drug: T-Gel 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-Gel 0.1% MD (multidose)
Trial: 16622086
Drug: T-Gel 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-Gel 0.1% SDU (single dose unit)
Trial: 16622086
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (T-Gel 0.1% MD and T-Gel 0.1% SDU)
Trial: 6529776
Drug: Terconazole (R-42470)
RxNorm normalized name: Terconazole
DrugBank: Terconazole (DB00251)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Terconazole (R-42470) cream 0.4%
Trial: 2189989
Drug: Clotrimazole cream
RxNorm normalized name: Clotrimazole Cream
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clotrimazole cream 1%
Trial: 31450520
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy (OT), Nordic walking (NW), and therapeutic touch (TT)
Trial: 25389256
Drug: Darunavir/ritonavir 800/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darunavir/ritonavir 800/100 mg
Trial: 23110478
Drug: Topical Negative
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Negative Pressure (TNP) with dermal substitute
Trial: 23110478
Drug: Topical Negative
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Negative Pressure (TNP) without dermal substitute
Trial: 20213205
Drug: Primary care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary care office-based buprenorphine/naloxone treatment (dosage and duration not specified)
Trial: 17541206
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitors (SSRIs) for approximately 12 weeks
Trial: 11825814
Drug: Brimonidine, 0.2%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine, 0.2%, twice a day
Trial: 2651758
Drug: 1,25(OH)2D3 at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,25(OH)2D3 at a dose of 0.25 to 0.5 microgram daily
Trial: 1105116
Drug: Atrovent (parasympatholytic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrovent (parasympatholytic drug)
Trial: 28804985
Drug: Virtual Reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual Reality Cue Exposure Therapy (CET)
Trial: 19203988
Drug: Lactobacillus rhamnosus
RxNorm normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus rhamnosus 2 x 10(8) CFU/day (Low-dose group)
Trial: 19203988
Drug: Lactobacillus rhamnosus
RxNorm normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus rhamnosus 6 x 10(8) CFU/day (High-dose group)
Trial: 19443680
Drug: Piperacillin/Tazobactam 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin/Tazobactam 4.5 g
Trial: 16758382
Drug: Piperacillin 4
RxNorm normalized name: piperacillin 4000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin 4 g
Trial: 10988100
Drug: Budesonide (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (400 microgram, twice daily)
Trial: 6531660
Drug: Omeprazole 80
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole 80 mg (initial loading dose)
Trial: 6531660
Drug: Histamine H2-receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine H2-receptor antagonists (high doses)
Trial: 22124360
Drug: High-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose group (3700 MBq)
Trial: 16571960
Drug: Sugammadex 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 2.0 mg/kg or greater
Trial: 11764220
Drug: Rofecoxib (COX-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib (COX-2 specific inhibitor)
Trial: 9432788
Drug: Hypooxyradiotherapy (HRT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypooxyradiotherapy (HRT) - 923 patients, pre-operative dosage increased by 50% (single dose - 6 Gy; total dose - 30 Gy; 54 isoGy) for stomach cancer
Trial: 9432788
Drug: Hypooxyradiotherapy (HRT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypooxyradiotherapy (HRT) - 923 patients, pre-operative dosage increased by 25% (single dose - 5 Gy; total dose - 25 Gy; 40 isoGy) for colonic cancer
Trial: 9432788
Drug: Hypooxyradiotherapy (HRT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypooxyradiotherapy (HRT) - 923 patients, pre-operative irradiation with a single HRT dose of 10 Gy (28 isoGy) for breast tumors reduced time of irradiation 4 times
Trial: 8217066
Drug: complementary drug
RxNorm normalized name: 20-mer complementary to Akt mRNA
DrugBank: Archexin (DB05971)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: complementary drug treatment for non-responders
Trial: 10282583
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group (drugs with computer-generated prompts)
Trial: 26885697
Drug: AlgaeCal calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AlgaeCal calcium supplement (AC)
Trial: 21989041
Drug: Focused shockwave
RxNorm normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focused shockwave therapy
Trial: 21989041
Drug: Radial shockwave
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial shockwave therapy
Trial: 21989041
Drug: Both interventions
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both interventions (Focused and Radial shockwave therapy)
Trial: 16930211
Drug: Acamprosate (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acamprosate (2 tablets of 333 mg t.i.d.)
Trial: 11124307
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination dorzolamide 2% and timolol 0.5% therapy
Trial: 11124307
Drug: Concomitant administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concomitant administration of a topical beta-blocker and dorzolamide
Trial: 25022840
Drug: 17DD-YF vaccine
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17DD-YF vaccine subdose of 587 IU
Trial: 25022840
Drug: 17DD-YF vaccine
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17DD-YF vaccine subdose of 3,013 IU
Trial: 25022840
Drug: Current dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current dose of 17DD-YF vaccine (27,476 IU)
Trial: 15661551
Drug: Tamoxifen treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen treatment (2 years)
Trial: 12464864
Drug: Preoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral intake of a formula enriched with arginine and n‐3 fatty acids for 5 days before surgery (pre‐op group)
Trial: 12464864
Drug: Same preoperative
RxNorm normalized name: SAMe
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same preoperative treatment prolonged after surgery by jejunal infusion (peri‐op group)
Trial: 9798803
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg o.d.
Trial: 9690720
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg t.d.s.
Trial: 9690720
Drug: Lansoprazole 60
RxNorm normalized name: dexlansoprazole 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 60 mg o.d.
Trial: 9690720
Drug: Lansoprazole 60
RxNorm normalized name: dexlansoprazole 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 60 mg b.d.
Trial: 9690720
Drug: Lansoprazole 60
RxNorm normalized name: dexlansoprazole 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 60 mg t.d.s.
Trial: 9690720
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg b.d. and t.d.s.
Trial: 9690720
Drug: Lansoprazole 60
RxNorm normalized name: dexlansoprazole 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 60 mg b.d. and t.d.s.
Trial: 9690720
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg t.d.s., 60 mg b.d. and 60 mg t.d.s.
Trial: 8845493
Drug: Dose escalation
RxNorm normalized name: PALFORZIA Initial Dose Escalation KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation therapy
Trial: 8845493
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy management
Trial: 2712613
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (local steroids + physiotherapy)
Trial: 28531361
Drug: EV 4
RxNorm normalized name: Zirabev 400 MG in 16 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV 4 mg
Trial: 28531361
Drug: EV 9
RxNorm normalized name: Summer's Eve Medicated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV 9 mg
Trial: 28531361
Drug: EV 4
RxNorm normalized name: Zirabev 400 MG in 16 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV 4 mg and EV 9 mg
Trial: 28116437
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of Beyond LED whitening and fluoride removal agent
Trial: 24955610
Drug: 12-month lifestyle
RxNorm normalized name: moth bean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-month lifestyle plus metformin intervention
Trial: 22782367
Drug: Subcutaneous fat
RxNorm normalized name: Sus scrofa subcutaneous fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous fat thickness ≥23 mm
Trial: 20103777
Drug: Hypokalemia (serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypokalemia (serum potassium <4 mEq/L)
Trial: 20103777
Drug: Normokalemia (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normokalemia (4 to 4.9 mEq/L)
Trial: 20103777
Drug: Mild hypokalemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild hypokalemia (3.5 to 3.9 mEq/L)
Trial: 20103777
Drug: Hypokalemia (<4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypokalemia (<4 mEq/L)
Trial: 7776510
Drug: buprenorphine 5
RxNorm normalized name: buprenorphine 5.7 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: buprenorphine 5 micrograms in 1 ml of 0.25% bupivacaine (group B)
Trial: 7776510
Drug: buprenorphine 8
RxNorm normalized name: buprenorphine 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: buprenorphine 8 micrograms in 1 ml of 0.25% bupivacaine (group C)
Trial: 7776510
Drug: buprenorphine 12
RxNorm normalized name: buprenorphine 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: buprenorphine 12 micrograms in 1 ml of 0.25% bupivacaine (group D)
Trial: 7776510
Drug: buprenorphine 15
RxNorm normalized name: BUPRENORPHINE 15MCG/HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: buprenorphine 15 micrograms in 1 ml of 0.25% bupivacaine (group E)
Trial: 7776510
Drug: buprenorphine 18
RxNorm normalized name: buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: buprenorphine 18 micrograms in 1 ml of 0.25% bupivacaine (group F)
Trial: 378140
Drug: Perioperative administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative administration of cefamandole plus five days of placebo
Trial: 378140
Drug: Perioperative plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative plus five days of postoperative antibiotic therapy
Trial: 378140
Drug: Perioperative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative therapy alone
Trial: 378140
Drug: Perioperative plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative plus 5-7 days of postoperative treatment
Trial: 378140
Drug: Appropriate prophylactic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Appropriate prophylactic antibiotic
Trial: 23351013
Drug: MMF withdrawal
RxNorm normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF withdrawal (2 g/d)
Trial: 21069309
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg tolterodine (twice a day)
Trial: 19587891
Drug: Fluor Kin
RxNorm normalized name: Fluor a Day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluor Kin antisarro dentifrice (0.32% sodium fluoride, 4.1% tetrapotassium pyrophosphate, 2.0% PVM/MA copolymer, 1.0% provitamin B5, 0.2% vitamin B3) used twice a day for 2 minutes for 3 months
Trial: 17459739
Drug: Oxatomide treatment
RxNorm normalized name: oxatomide
DrugBank: Oxatomide (DB12877)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxatomide treatment for 6 months
Trial: 17459739
Drug: Medication-free lead-in
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication-free lead-in period for 3 months
Trial: 16316358
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron sucrose (300 mg)
Trial: 9624242
Drug: Pre-operative chemotherapy
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative chemotherapy (cisplatin and etoposide)
Trial: 7828190
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral sumatriptan (group I)
Trial: 7828190
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral sumatriptan (group I) for treating headache recurrence
Trial: 3254614
Drug: Glucagon (0.25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucagon (0.25, 0.5, 1.0, or 2.0 mg)
Trial: 3254614
Drug: G-(1-21) (0.175,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-(1-21) (0.175, 0.35, 0.70, or 1.4 mg)
Trial: 23939351
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion strategy (Hb trigger, 70 g/L; target, 71-90 g/L)
Trial: 23939351
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (Hb trigger, 90 g/L; target, 91-110 g/L)
Trial: 16600984
Drug: Gemcitabine (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1500 mg/m²) followed by oxaliplatin (85 mg/m²) on day 1 and 15 of a 28-day cycle
Trial: 16600984
Drug: Gemcitabine-oxaliplatin (GEMOX)
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine-oxaliplatin (GEMOX) combination
Trial: 11001084
Drug: Specialist asthma
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specialist asthma nurse intervention with three 6-weekly outpatient appointments for structured asthma consultation.
Trial: 27225336
Drug: Non-treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-treatment
Trial: 20962793
Drug: Oral erectile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral erectile medications (specific medications not mentioned), administered for two 3-month phases.